Study finds nerve damage in previously
mysterious chronic pain syndrome
Reduction in small-fiber nerves may underlie complex regional
pain syndrome-I (reflex sympathetic dystrophy)
BOSTON—Researchers at Massachusetts General Hospital
(MGH) have found the first evidence of a physical abnormality
underlying the chronic pain condition called reflex sympathetic
dystrophy or complex regional pain syndrome-I (CRPS-I). In
the February issue of the journal Pain, they describe finding
that skin affected by CRPS-I pain appears to have lost some
small-fiber nerve endings, a change characteristic of other
neuropathic pain syndromes.
"This sort of small-fiber degeneration has been found
in every nerve pain condition ever studied, including postherpetic
neuralgia and neuropathies associated with diabetes and HIV
infection," says Anne Louise Oaklander, MD, PhD, director
of the MGH Nerve Injury Unit, who led the study. "The
nerve damage in those conditions has been much more severe,
which may be why it's been so hard to detect CRPS-I-related
nerve damage."
Complex regional pain syndrome is the current name for a
baffling condition first described in the 19th century in
which some patients are left with severe chronic pain and
other symptoms swelling, excess sweating, change in
skin color and temperature after what may be a fairly
minor injury. The fact that patients' pain severity is
out of proportion to the original injury is a hallmark of
the syndrome, and has led many to doubt whether patients'
symptoms are caused by physical damage or by a psychological
disorder. Pain not associated with a known nerve injury has
been called CRPS-I, while symptoms following damage to a major
nerve has been called CRPS-II.
Because small-fiber nerve endings transmit pain messages
and control skin color and temperature and because damage
to those fibers is associated with other painful disorders,
the MGH research team hypothesized that those fibers might
also be involved with CRPS-I. To investigate their theory
they studied 18 CRPS-I patients and 7 control patients with
similar chronic symptoms known to be caused by arthritis.
Small skin biopsies were taken under anesthesia from the most
painful area, from a pain-free area on the same limb and from
a corresponding unaffected area on the other side of the body.
The skin biopsies showed that, the density of small-fiber
nerve endings in CRPS-I patients was reduced from 25 to 30
percent in the affected areas compared with unaffected areas.
No nerve losses were seen in samples from the control participants,
suggesting that the damage was specific to CRPS-I, not to
pain in general. Tests of sensory function performed in the
same areas found that a light touch or slight heat was more
likely to be perceived as painful in the affected areas of
CRPS-I patients than in the unaffected areas, also indicating
abnormal neural function.
"The fact that CRPS-I now has an identified cause takes
it out of the realm of so-called psychosomatic illness.'
One of the great frustrations facing CRPS-I patients has been
the lack of an explanation for their symptoms. Many people
are skeptical of their motivations, and some physicians are
reluctant to prescribe pain medications when the cause of
pain is unknown," says Oaklander. "Our results suggest
that CRPS-I patients should be evaluated by neurologists who
specialize in nerve injury and be treated with medications
or procedures that have proven effective for other nerve-injury
pain syndromes." She adds that the next research steps
should investigate why some people are left with CRPS after
injuries that do not cause long-term problems for most patients,
determine the best way of diagnosing the syndrome and evaluate
potential treatments.
"Investigations that identify the causes of disease
are only possible if patients are willing to come to the lab
and allow researchers to study them," she adds. "We
are tremendously grateful to these CRPS patients, whose willingness
to let us study them despite their chronic pain
allowed us to make an important step in helping those who
suffer from this condition." Oaklander is an assistant
professor of Anaesthesia and Neurology at Harvard Medical
School.
The study was supported by grants from The Mayday Fund, the
National Institute for Neurological Disorders and Stroke,
and the American Federation for Aging Research. Coauthors
are Julia Rissmiller, Lisa Gelman, Li Zheng, MD, PhD; Yuchiao
Chang, PhD; and Ralph Gott, all of the MGH.
Massachusetts General Hospital, established in 1811, is the
original and largest teaching hospital of Harvard Medical
School. The MGH conducts the largest hospital-based research
program in the United States, with an annual research budget
of nearly $500 million and major research centers in AIDS,
cardiovascular research, cancer, cutaneous biology, medical
imaging, neurodegenerative disorders, transplantation biology
and photomedicine. In 1994, MGH and Brigham and Women's
Hospital joined to form Partners HealthCare System, an integrated
health care delivery system comprising the two academic medical
centers, specialty and community hospitals, a network of physician
groups, and nonacute and home health services.
Updated January 31, 2006
|